Melanoma Clinical Trials in San Francisco, California

10 studies are recruiting for melanoma in San Francisco, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California San Francisco, San Francisco, California

   Locations

   48 in total

   Run by

   Pierre Fabre Medicament

   See if you can join NCT04913285 on ClinicalTrials.gov

2. Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

   This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may hel…

   Stage

   Phase 1

   Ages

   1 to 30

   Site

   UCSF Medical Center-Mission Bay, San Francisco, California

   Locations

   21 in total

   Run by

   Children's Oncology Group

   See if you can join NCT04851119 on ClinicalTrials.gov

3. A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

   This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of California San Francisco (UCSF), San Francisco, California

   Locations

   111 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT06246916 on ClinicalTrials.gov

4. Intratumoral N17350 in Advanced Solid Tumors

   The goal of this clinical trial is to learn if N17350 works to treat advanced solid tumors in adults. It will also learn about the safety of N17350 and help determine the best dose to use in future studies. The main questions it aims to answer are: 1. Does N17350 cause tumors to shrink or stop grow…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Locations

   8 in total

   Run by

   Onchilles Pharma Inc

   See if you can join NCT07339176 on ClinicalTrials.gov

5. Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

   This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to…

   Stage

   Phase 3

   Ages

   18 to 70

   Site

   California Pacific Medical Center, San Francisco, California

   Locations

   81 in total

   Run by

   Iovance Biotherapeutics, Inc.

   See if you can join NCT05727904 on ClinicalTrials.gov

6. A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

   This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe, tolerable, and eff…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California San Francisco (UCSF), San Francisco, California

   Locations

   11 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT06413680 on ClinicalTrials.gov

7. A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

   This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment opti…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   23 in total

   Run by

   Nested Therapeutics, Inc

   See if you can join NCT06326411 on ClinicalTrials.gov

8. Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

   This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies with chemotherapy and/or (immune checkpoint inhibitors) ICIs.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Kaiser Permanente-San Francisco, San Francisco, California

   Locations

   467 in total

   Run by

   Wake Forest University Health Sciences

   See if you can join NCT06418204 on ClinicalTrials.gov

9. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, San Francisco, California

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov

10. A Study of IBI363 in Subjects with Advanced Solid Malignancies

    This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of California, San Francisco (UCSF), San Francisco, California

    Locations

    9 in total

    Run by

    Innovent Biologics (Suzhou) Co. Ltd.

    See if you can join NCT06281678 on ClinicalTrials.gov